Physician profile
Robert L Robles
NPI 1518963958
$6,779.44
in general payments reported to CMS, 2019-2025
56 companies · $30.80 in 2025
The $30.80 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $979 · 2021: $1,442 · 2022: $951 · 2023: $1,677 · 2024: $561 · 2025: $30.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Education: $95.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.68 |
| Education | $95.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $740.06 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Janssen Biotech, INC. | $522.83 | 2019-2024 | Erleada, Imbruvica, Akeega |
| E.R. Squibb & Sons, L.L.C. | $513.71 | 2019-2023 | Opdivo |
| Pfizer INC. | $394.72 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $354.94 | 2019-2023 | Imbruvica, Epkinly |
| Seagen INC. | $305.33 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Kite Pharma, INC. | $281.91 | 2019-2023 | Yescarta |
| Novartis Pharmaceuticals Corporation | $256.22 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $225.27 | 2019-2023 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $210.28 | 2020-2024 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $207.82 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $204.80 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $200.00 | 2022 | |
| Portola Pharmaceuticals, LLC | $182.25 | 2019-2020 | |
| Array Biopharma INC | $168.82 | 2019-2023 | Mektovi, Braftovi, Lorbrena |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.